OraSure Technologies Files Proxy Statement

TL;DR

ORASURE filed its proxy statement, no fee needed. Standard procedure.

AI Summary

OraSure Technologies, Inc. filed a Definitive Proxy Statement (DEFA14A) on December 17, 2025, related to soliciting material under Rule 14a-12. The filing indicates no fee was required for this submission. The company is headquartered at 220 E First St, Bethlehem, PA 18015.

Why It Matters

This filing is a routine proxy statement, indicating the company is preparing for shareholder engagement or specific corporate actions requiring shareholder approval or notification.

Risk Assessment

Risk Level: low — This is a standard DEFA14A filing, which is a routine disclosure document for public companies.

Key Numbers

• 20251217 — Filing Date (The date the DEFA14A was filed with the SEC.)

Key Players & Entities

• OraSure Technologies, Inc. (company) — Registrant
• 220 E First St, Bethlehem, PA 18015 (location) — Company Business Address
• 0001116463-25-000060 (filing_id) — Accession Number

FAQ

Key Financial Figures

• $216 million — aintaining a healthy cash position with $216 million of cash on the balance sheet as of Sept
• $40 million — year our Board began executing on a new $40 million share repurchase program. In addition,

Filing Documents

• osurdefa14a121725.htm (DEFA14A) — 45KB
• image_0.jpg (GRAPHIC) — 0KB
• image_1.jpg (GRAPHIC) — 29KB
• 0001116463-25-000060.txt ( ) — 87KB

Forward-Looking Statements

Forward-Looking Statements This press release contains certain forward-looking statements, including with respect to OraSure's board of directors, OraSure's business strategy, and other matters. Forward-looking statements are not 1 Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG). guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to our ability to satisfy customer demand ability to reduce our spending rate, capitalize on manufacturing efficiencies and drive profitable growth ability to market and sell our products and services, whether through our internal, direct sales force or third parties impact of significant customer concentration in the genomics business failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products significant customer concentrations that exist or may develop in the future ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products ability to comply with applicable regulatory requirements ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements impact of replacing distributors inventory levels at distributors and other customers our ability to achieve its financial and strategic objectives and increase our revenues, including the ability to expand int

View Full Filing

View this DEFA14A filing on SEC EDGAR